Chinese drug regulation proposals spell big changes for industry
This article was originally published in SRA
The China Food and Drug Administration has proposed amendments to the Drug Registration Regulation (DRR) that could introduce significant changes for pharmaceutical companies operating in China1,2.
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New medicines under evaluation at the European Medicines Agency.
The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.